Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-east of France Group Study

Prog Clin Biol Res. 1994:385:293-300.

Authors

J Michon¹, S Négrier, C Coze, C Mathiot, D Frappaz, R Oskam, H Pacquement, E Quintana, E Bouffet, J L Bernard, et al.

Affiliation

¹ Biotherapy Unit, Institut Curie, Paris, France.

PMID: 7972223

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase II
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Bone Marrow Transplantation*
Child
Child, Preschool
Female
France
Humans
Infant
Infusions, Intravenous
Interleukin-2 / administration & dosage
Interleukin-2 / adverse effects
Interleukin-2 / therapeutic use*
Male
Neuroblastoma / therapy*
Prognosis
Recombinant Proteins / administration & dosage
Recombinant Proteins / adverse effects
Recombinant Proteins / therapeutic use
Remission Induction
Survival Analysis
Transplantation, Autologous

Substances

Interleukin-2
Recombinant Proteins